Non-Us was Ptc Therapeutics’s largest region in fiscal 2025, bringing in $334.52M of $921.22M (36%).
| Geography | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Non-Us | $332.75M | $374.93M | $334.52M | ||||||
| All Other Countries | $238.51M | $197.47M | $168.41M | ||||||
| United States | $255.09M | — | $252.19M | ||||||
| Russia | — | $105.38M | $100.45M | ||||||
| Brazil | $58.61M | $72.08M | $65.66M | ||||||
| Total | $884.96M | $749.86M | $921.22M |
Ptc Therapeutics brought in $921.22M from its five regions in fiscal 2025, the year ended December 31, 2025. Ptc Therapeutics regrouped these regions after fiscal 2024, so the total does not compare directly with that year's $749.86M. Non-Us was the largest at $334.52M (36.3%), ahead of United States at $252.19M (27.4%) and All Other Countries at $168.41M (18.3%). The other two regions brought in $166.11M combined.
Compared with fiscal 2024, every region above 2% of revenue shrank. Russia held up best, down 4.7% to $100.45M, and All Other Countries fell the most, down 14.7% to $168.41M.
Ptc Therapeutics began breaking out Russia in fiscal 2024, when it brought in $105.38M.
Royalty Revenue was Ptc Therapeutics’s largest product and service line in fiscal 2024, bringing in $407.76M of $482.43M (85%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2018 | FY 2018 | FY 2018 | FY 2019 | FY 2019 | FY 2019 | FY 2019 | FY 2020 | FY 2020 | FY 2020 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Translarna | — | — | $332.75M | $18.81M | ||||||||||||||
| Royalty Revenue | $54.64M | $227.02M | $337.76M | $407.76M | ||||||||||||||
| Emflaza | $187.30M | — | — | — | ||||||||||||||
| Net Product Revenue | $241.60M | $376.60M | — | — | ||||||||||||||
| Collaboration Revenue | $55.05M | $100.15M | $100.00M | — | ||||||||||||||
| Collaboration & License Revenue | — | — | $100.03M | $304.00K | ||||||||||||||
| All Other Products | — | — | $31.50M | $36.95M | ||||||||||||||
| Upstaza/Kebilidi | — | — | $18.84M | $16.91M | ||||||||||||||
| Collaboration & Grant Revenue | — | — | — | — | ||||||||||||||
| Manufacturing Revenue | — | — | $7.70M | $1.70M | ||||||||||||||
| Grant | — | — | — | — | ||||||||||||||
| Total | $538.59M | $703.77M | $928.58M | $482.43M |
Ptc Therapeutics brought in $482.43M from its six product and service lines in fiscal 2024, the year ended December 31, 2024. Ptc Therapeutics regrouped these lines after fiscal 2023, so the total does not compare directly with that year's $928.58M. Royalty Revenue was the largest at $407.76M (84.5%), ahead of All Other Products at $36.95M (7.7%) and Translarna at $18.81M (3.9%). The other three lines brought in $18.92M combined.
Compared with fiscal 2023, Royalty Revenue grew fastest, up 20.7% to $407.76M, while Translarna fell the most, down 94.3% to $18.81M.
Ptc Therapeutics began breaking out Collaboration & License Revenue in fiscal 2023, All Other Products in fiscal 2023, Upstaza/Kebilidi in fiscal 2023 and Manufacturing Revenue in fiscal 2023. Ptc Therapeutics stopped reporting Net Product Revenue ($376.60M in fiscal 2022), Emflaza ($187.30M in fiscal 2021) and Collaboration Revenue ($100.00M in fiscal 2023) as separate lines.
Ptc Therapeutics (PTCT) reports its revenue by geography and by product and service. In fiscal 2025, Non-Us was its largest region, bringing in $334.52M (36.3% of the total), followed by United States at $252.19M (27.4%).
Non-Us was Ptc Therapeutics' largest region in fiscal 2025, bringing in $334.52M, or 36.3% of the $921.22M total across its five regions.
Royalty Revenue was Ptc Therapeutics' largest product and service line in fiscal 2024, bringing in $407.76M, or 84.5% of the $482.43M total across its six product and service lines.
Every figure comes from Ptc Therapeutics' annual financial filings, as reported. Each line keeps the name Ptc Therapeutics gives it, and years follow its fiscal calendar.
Ptc Therapeutics' revenue by geography goes back to fiscal 2015, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.